Evidence Hub

Comparative in vitro activity of garenoxacin (BMS-284756). Sentry program, Spain (1999-2000)

Loza E, Cantón R, Pascual A, Tubau F, Morosini MI, Almaraz F, Perea E, Martín R et al.

Enfermedades infecciosas y microbiologia clinica, 2003

Abstract

INTRODUCTION: To evaluate the in vitro activity of the new des-fluoro quinolone, garenoxacin (BMS-284756), compared to activities of ciprofloxacin, levofloxacin, and gatifloxacin in clinical isolates recovered over 1999 and 2000 within the SENTRY antimicrobial surveillance program.

METHODS: Quinolone-MICs were performed using the standard NCCLS microdilution technique in 2599 isolates recovered from Hospital Ramón y Cajal (Madrid), Virgen Macarena (Sevilla), and Bellvitge (Barcelona).

RESULTS: The modal MIC range value exhibited by garenoxacin ( < or = 0.03-0.12 mg/L) for Enterobacteriaceae was similar to that of the other quinolones tested. A total of 70% of Pseudomonas aeruginosa isolates were susceptible to garenoxacin and 85% to ciprofloxacin and levofloxacin. Garenoxacin exhibited the highest activity in Staphylococcus aureus, including both methicillin-susceptible and -resistant isolates, with MIC90 values of < or = 0.03 and 2 mg/L, respectively. All Streptococcus pneumoniae isolates were susceptible to garenoxacin, regardless of their penicillin susceptibility status; in terms of MIC90, garenoxacin was 16 times more active than ciprofloxacin and levofloxacin and 4-8 times more active than gatifloxacin. All 6 ciprofloxacin-resistant S. pneumoniae strains showed garenoxacin MIC values ranging from < or = 0.03 to 0.5 mg/L. In Haemophilus influenzae and Moraxella catarrhalis, garenoxacin displayed excellent in vitro activity (MIC < or = 0.06 mg/L), similar to that of the…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free